INVO Bioscience Expands Firm-Owned Clinic Possibility Underneath Amended U.S. Commercialization Settlement

SARASOTA, Fla., March 8, 2021 /PRNewswire/ — INVO Bioscience, Inc. (NASDAQ: INVO), a medical unit firm targeted on commercializing the world’s only in vivo Intravaginal Society System (IVC), INVOcell®, an effective and affordable procedure for sufferers identified with infertility, today declared an amendment less than its unique U.S. commercialization settlement with Ferring Prescribed drugs. The modification gives for an increase in the number of INVO firm-owned clinics in the beginning allowable underneath the arrangement and eliminates selected geographical restrictions.

INVO Bioscience, Inc. is a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell, the world's only in vivo Intravaginal Culture System (IVC) used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development. (PRNewsfoto/INVO Bioscience, Inc.)

INVO Bioscience, Inc. is a clinical system enterprise concentrated on generating different treatments for individuals identified with infertility and developers of INVOcell, the world’s only in vivo Intravaginal Culture Program (IVC) utilised for the normal in vivo incubation of eggs and sperm during fertilization and early embryo development. (PRNewsfoto/INVO Bioscience, Inc.)

Steve Shum, CEO of INVO Bioscience, commented, “We are delighted to have properly done this amendment with our U.S. lover, Ferring. We think it demonstrates the power of our ongoing collaboration and shared determination to grow the use of INVOcell in the U.S. We also feel our devoted clinic approach is an critical complementary channel to accelerate consciousness and marketplace adoption of INVOcell and in our viewpoint will let us to capture added for every-course of action money. In our watch, this strategy will increase marketplace ability, affordability and facilitate larger access for sufferers. We anticipate to report on our original U.S. functions in the around long run.”

The amendment also altered the remaining once-a-year 2020 minimum amount contractual product buy need, whereby Ferring will area a $501,000 buy, which will be acknowledged as income by INVO Bioscience in the very first quarter of 2021.

About INVO Bioscience

We are a professional medical product enterprise focused on creating simplified, lower-value therapies for patients identified with infertility. Our resolution, the INVO® Technique, is a groundbreaking in vivo system of vaginal incubation that offers patients a additional purely natural and intimate knowledge. Our lead products, the INVOcell®, is a patented clinical machine used in infertility treatment method and is viewed as an Assisted Reproductive Technological innovation (Art). The INVOcell® is the initial Intravaginal Lifestyle (IVC) procedure in the entire world used for the organic in vivo incubation of eggs and sperm all through fertilization and early embryo improvement, as an alternative to conventional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to maximize entry to care and grow fertility treatment method across the world with a goal to reduced the expense of care and enhance the availability of treatment. For far more details, be sure to pay a visit to http://invobioscience.com/

Safe and sound Harbor Statement

This release involves ahead-seeking statements inside the which means of Portion 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Exchange Act of 1934, as amended. The Firm invokes the protections of the Personal Securities Litigation Reform Act of 1995. All statements concerning our envisioned future money placement, success of operations, funds flows, funding programs, business enterprise techniques, solutions and providers, competitive positions, progress chances, options and aims of management for foreseeable future operations, as nicely as statements that include terms this sort of as “anticipate,” “if,” “think,” “system,” “estimate,” “expect,” “intend,” “might,” “could,” “should,” “will,” and other equivalent expressions are forward-looking statements. All ahead-searching statements involve risks, uncertainties and contingencies, quite a few of which are further than our handle, which may well result in real outcomes, performance, or achievements to differ materially from expected benefits, overall performance, or achievements. Things that could result in real success to vary materially from these in the ahead-looking statements contain these established forth in our filings at www.sec.gov. We are underneath no obligation to (and expressly disclaim any these types of obligation to) update or change our ahead-hunting statements, whether or not as a final result of new info, upcoming functions or or else.

Cision

Cision

Watch primary content to down load multimedia:http://www.prnewswire.com/news-releases/invo-bioscience-expands-corporation-owned-clinic-possibility-underneath-amended-us-commercialization-agreement-301242697.html

Resource INVO Bioscience, Inc.